1363 studies found for:    "Chronic lymphocytic leukemia"
Show Display Options
Rank Status Study
21 Terminated Obatoclax, Fludarabine, and Rituximab in Treating Patients With Previously Treated Chronic Lymphocytic Leukemia
Conditions: B-cell Chronic Lymphocytic Leukemia;   Leukemia;   Prolymphocytic Leukemia;   Refractory Chronic Lymphocytic Leukemia;   Stage I Chronic Lymphocytic Leukemia;   Stage II Chronic Lymphocytic Leukemia;   Stage III Chronic Lymphocytic Leukemia;   Stage IV Chronic Lymphocytic Leukemia
Interventions: Drug: obatoclax mesylate;   Drug: fludarabine phosphate;   Biological: rituximab;   Other: laboratory biomarker analysis
22 Active, not recruiting A Phase 1b Study Evaluating the Safety and Tolerability of ABT-199 in Combination With Rituximab in Subjects With Relapsed Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
Conditions: Small Lymphocytic Lymphoma;   Chronic Lymphocytic Leukemia
Interventions: Drug: ABT-199;   Drug: Rituximab
23 Terminated Alvocidib in Treating Patients With B-Cell Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Conditions: B-cell Chronic Lymphocytic Leukemia;   Contiguous Stage II Small Lymphocytic Lymphoma;   Noncontiguous Stage II Small Lymphocytic Lymphoma;   Stage I Chronic Lymphocytic Leukemia;   Stage I Small Lymphocytic Lymphoma;   Stage II Chronic Lymphocytic Leukemia;   Stage III Chronic Lymphocytic Leukemia;   Stage III Small Lymphocytic Lymphoma;   Stage IV Chronic Lymphocytic Leukemia;   Stage IV Small Lymphocytic Lymphoma
Interventions: Drug: alvocidib;   Other: pharmacological study;   Other: laboratory biomarker analysis
24 Active, not recruiting Imprime PGG, Alemtuzumab, and Rituximab in Treating Patients With High Risk Chronic Lymphocytic Leukemia
Conditions: B-cell Chronic Lymphocytic Leukemia;   Refractory Chronic Lymphocytic Leukemia;   Stage 0 Chronic Lymphocytic Leukemia;   Stage I Chronic Lymphocytic Leukemia;   Stage II Chronic Lymphocytic Leukemia
Interventions: Biological: alemtuzumab;   Biological: rituximab;   Drug: PGG beta-glucan;   Other: flow cytometry;   Other: laboratory biomarker analysis;   Genetic: DNA analysis;   Genetic: fluorescence in situ hybridization;   Genetic: polymerase chain reaction;   Genetic: polymorphism analysis;   Genetic: mutation analysis
25 Active, not recruiting Vorinostat, Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic
Conditions: B-cell Chronic Lymphocytic Leukemia;   Contiguous Stage II Small Lymphocytic Lymphoma;   Noncontiguous Stage II Small Lymphocytic Lymphoma;   Stage I Chronic Lymphocytic Leukemia;   Stage I Small Lymphocytic Lymphoma;   Stage II Chronic Lymphocytic Leukemia;   Stage III Chronic Lymphocytic Leukemia;   Stage III Small Lymphocytic Lymphoma;   Stage IV Chronic Lymphocytic Leukemia;   Stage IV Small Lymphocytic Lymphoma
Interventions: Drug: fludarabine phosphate;   Drug: cyclophosphamide;   Biological: rituximab;   Drug: vorinostat
26 Recruiting Fludarabine Phosphate, Radiation Therapy, and Rituximab in Treating Patients Who Are Undergoing Donor Stem Cell Transplant Followed by Rituximab for High-Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Conditions: B-cell Chronic Lymphocytic Leukemia;   Prolymphocytic Leukemia;   Recurrent Small Lymphocytic Lymphoma;   Refractory Chronic Lymphocytic Leukemia;   Stage III Chronic Lymphocytic Leukemia;   Stage III Small Lymphocytic Lymphoma;   Stage IV Chronic Lymphocytic Leukemia;   Stage IV Small Lymphocytic Lymphoma;   T-cell Large Granular Lymphocyte Leukemia
Interventions: Drug: fludarabine phosphate;   Biological: rituximab;   Radiation: total-body irradiation;   Procedure: allogeneic hematopoietic stem cell transplantation;   Procedure: peripheral blood stem cell transplantation;   Drug: cyclosporine;   Drug: mycophenolate mofetil;   Other: laboratory biomarker analysis;   Other: pharmacological study
27 Recruiting Lenalidomide and Vaccine Therapy in Treating Patients With Early-Stage Asymptomatic Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Conditions: B-cell Chronic Lymphocytic Leukemia;   Contiguous Stage II Small Lymphocytic Lymphoma;   Noncontiguous Stage II Small Lymphocytic Lymphoma;   Stage 0 Chronic Lymphocytic Leukemia;   Stage I Chronic Lymphocytic Leukemia;   Stage I Small Lymphocytic Lymphoma;   Stage II Chronic Lymphocytic Leukemia
Interventions: Biological: pneumococcal polyvalent vaccine;   Drug: lenalidomide;   Other: pharmacological study;   Other: laboratory biomarker analysis
28 Active, not recruiting PCI-32765 for Special Cases of Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Conditions: Leukemia;   Leukemia, Lymphocytyc;   CLL (Chronic Lymphocytic Leukemia);   SLL (Small Lymphocytic Lymphoma)
Intervention: Drug: PCI 32765
29 Recruiting Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Conditions: Anemia;   Fever, Sweats, and Hot Flashes;   Stage I Chronic Lymphocytic Leukemia;   Stage I Small Lymphocytic Lymphoma;   Stage II Chronic Lymphocytic Leukemia;   Stage II Small Lymphocytic Lymphoma;   Stage III Chronic Lymphocytic Leukemia;   Stage III Small Lymphocytic Lymphoma;   Stage IV Chronic Lymphocytic Leukemia;   Stage IV Small Lymphocytic Lymphoma;   Weight Changes
Interventions: Drug: ibrutinib;   Drug: fludarabine phosphate;   Drug: cyclophosphamide;   Biological: rituximab;   Other: quality-of-life assessment;   Other: laboratory biomarker analysis
30 Not yet recruiting Curcumin and Cholecalciferol in Treating Patients With Previously Untreated Stage 0-II Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Conditions: Contiguous Stage II Small Lymphocytic Lymphoma;   Noncontiguous Stage II Small Lymphocytic Lymphoma;   Stage 0 Chronic Lymphocytic Leukemia;   Stage I Chronic Lymphocytic Leukemia;   Stage I Small Lymphocytic Lymphoma;   Stage II Chronic Lymphocytic Leukemia
Interventions: Dietary Supplement: curcumin;   Dietary Supplement: cholecalciferol;   Other: laboratory biomarker analysis;   Other: pharmacological study
31 Withdrawn Azadirachta Indica in Treating Patients With Chronic Lymphocytic Leukemia
Conditions: Refractory Chronic Lymphocytic Leukemia;   Stage II Chronic Lymphocytic Leukemia;   Stage III Chronic Lymphocytic Leukemia;   Stage IV Chronic Lymphocytic Leukemia
Interventions: Other: laboratory biomarker analysis;   Genetic: western blotting;   Genetic: gene expression analysis;   Other: pharmacological study;   Other: flow cytometry;   Genetic: fluorescence in situ hybridization;   Biological: azadirachta indica;   Genetic: reverse transcriptase-polymerase chain reaction
32 Completed
Has Results
Fludarabine, Rituximab, and Alemtuzumab in Treating Patients With Chronic Lymphocytic Leukemia
Conditions: B-cell Chronic Lymphocytic Leukemia;   Stage I Chronic Lymphocytic Leukemia;   Stage II Chronic Lymphocytic Leukemia;   Stage III Chronic Lymphocytic Leukemia;   Stage IV Chronic Lymphocytic Leukemia
Interventions: Biological: alemtuzumab;   Biological: rituximab;   Drug: fludarabine phosphate
33 Completed
Has Results
Perifosine in Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Conditions: Chronic Lymphocytic Leukemia;   Small Lymphocytic Lymphoma
Intervention: Drug: perifosine
34 Active, not recruiting Fludarabine and Rituximab With or Without Lenalidomide or Cyclophosphamide in Treating Patients With Symptomatic Chronic Lymphocytic Leukemia
Conditions: B-cell Chronic Lymphocytic Leukemia;   Stage I Chronic Lymphocytic Leukemia;   Stage II Chronic Lymphocytic Leukemia;   Stage III Chronic Lymphocytic Leukemia;   Stage IV Chronic Lymphocytic Leukemia
Interventions: Biological: rituximab;   Drug: fludarabine phosphate;   Drug: cyclophosphamide;   Drug: lenalidomide;   Other: laboratory biomarker analysis
35 Recruiting Phase I and II Study of Auranofin in Chronic Lymphocytic Leukemia (CLL)
Conditions: Chronic Lymphocytic Leukemia (CLL);   Small Lymphocytic Lymphoma;   Leukemia, Prolymphocytic
Intervention: Drug: auranofin
36 Completed
Has Results
Lenalidomide in Previously Treated Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Conditions: Chronic Lymphocytic Leukemia (CLL);   Small Lymphocytic Lymphoma
Intervention: Drug: Lenalidomide
37 Recruiting Lenalidomide and AT-101 in Treating Patients With Relapsed or Refractory B-Cell Chronic Lymphocytic Leukemia
Conditions: B-cell Chronic Lymphocytic Leukemia;   Refractory Chronic Lymphocytic Leukemia;   Stage III Chronic Lymphocytic Leukemia;   Stage IV Chronic Lymphocytic Leukemia
Interventions: Drug: lenalidomide;   Drug: R-(-)-gossypol acetic acid
38 Recruiting Alemtuzumab-Ofatumumab in Previously Untreated Symptomatic Chronic Lymphocytic Leukemia
Conditions: Stage I Chronic Lymphocytic Leukemia;   Stage II Chronic Lymphocytic Leukemia;   Stage III Chronic Lymphocytic Leukemia;   Stage IV Chronic Lymphocytic Leukemia
Interventions: Biological: alemtuzumab;   Biological: ofatumumab;   Procedure: biopsy
39 Completed Apolizumab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Conditions: Noncontiguous Stage II Small Lymphocytic Lymphoma;   Recurrent Small Lymphocytic Lymphoma;   Refractory Chronic Lymphocytic Leukemia;   Stage III Small Lymphocytic Lymphoma;   Stage IV Small Lymphocytic Lymphoma
Interventions: Biological: apolizumab;   Other: laboratory biomarker analysis;   Other: pharmacological study
40 Recruiting A Phase II Study of Ofatumumab-Based Induction Chemoimmunotheraphy Followed by Consolidation Ofatumumab Immunotherapy in Previously Untreated Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Conditions: Small Lymphocytic Lymphoma;   CLL (Chronic Lymphocytic Leukemia)
Interventions: Drug: Fludarabine Phosphate;   Biological: Ofatumumab;   Drug: Cyclophosphamide

Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results
Indicates status has not been verified in more than two years